ClinicalTrials.gg
RecruitingNCT07614542Updated May 29, 2026

AGEWISE: Unravelling the Gut-Hormone Axis in Women's Ageing

An observational study in Menopause, Gut Microbiome and Hormonal Changes, sponsored by Gulbenkian Institute for Molecular Medicine. Recruiting at 1 site in Portugal. Open to female participants aged 40 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-05-29.

Sponsored by Gulbenkian Institute for Molecular Medicine · Observational

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
300
Ages
40 Years to 64 Years
Sex
Female
01

Study summary

AGEWISE is an observational study that aims to understand how changes in gut microbiome are related to hormonal changes during women's ageing, particularly across the different stages of menopause. The study will include healthy women aged 40 to 64 years living in Portugal, who will provide stool and blood samples and complete questionnaires about their health, lifestyle, diet, and menopausal symptoms. Researchers will study the gut microbiome together with hormone levels and markers of inflammation to better understand how menopause affects long-term health and to support the development of improved prevention strategies for women.

Read the detailed description

AGEWISE aims to investigate the relationship between the gut microbiome, female sex hormones, chronic low-grade inflammation, and women's ageing across the menopausal transition.

The results will support the identification of microbiome-based and blood-based biomarkers associated with menopause and ageing, and contribute to the development of data-driven tools for personalised risk assessment and prevention strategies in women's health.

Primary Objective:

To identify and validate faecal microbiome biomarkers by analysing taxonomic and functional changes across different stages of menopause in women.

Secondary Objectives:

To explore associations between gut microbiome composition and female sex hormone levels, including estradiol, follicle-stimulating hormone (FSH), luteinizing hormone (LH), anti-Müllerian hormone (AMH), and cortisol.

To investigate the relationship between the gut microbiome and blood biomarkers of chronic low-grade inflammation (inflammaging).

To assess associations between microbiome profiles, clinical history, lifestyle, and dietary factors and the risk of conditions associated with menopause.

02

Conditions studied

  • Menopause
  • Gut Microbiome
  • Hormonal Changes
  • Chronic Low-Grade Inflammation
  • Inflammaging

Keywords

  • microbiome
  • biomarkers
  • metagenomics
  • menopausal transition
  • women's health
03

In context

Lead sponsor

Gulbenkian Institute for Molecular Medicine is the lead sponsor of 3 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 64 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participants are recruited using non-random, voluntary recruitment strategies. Eligible women are identified through open public calls, institutional outreach activities, existing biobank donor databases, and re-contact of participants from related research projects who have previously agreed to be contacted for future studies. Enrollment is based on predefined eligibility criteria and the individual's willingness to participate. All potential participants who meet the eligibility criteria receive detailed information about the study from the research team, and those who agree to take part are required to provide written informed consent prior to participation.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female sex
  • Aged 40 to 64 years
  • Resident in mainland Portugal or the islands
  • Able and willing to provide written
  • Willing to provide stool and blood samples and complete three questionnaires

Exclusion criteria

Exclusion Criteria:

  • Age below 40 years or 65 years and older
  • Inability to give
  • Refusal to provide stool or blood samples or complete questionnaires
  • Pregnancy
  • Diagnosed gastrointestinal disorders (including inflammatory bowel disease, Crohn's disease, ulcerative colitis, irritable bowel syndrome, chronic diarrhoea of unknown cause, or recurrent Clostridioides difficile infection)
  • Active oncological disease
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
300 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Premenopausal women (self-reported)

    Regular menstrual periods, with no signs of menopause yet.

  • Perimenopausal women (self-reported)

    Irregular menstrual periods, presence of some menopausal symptoms, such as hot flashes, mood changes, sleep disturbances, and brain fog.

  • Menopausal/Postmenopausal women (self-reported)

    Absence of menstruation for 12 consecutive months.

06

What researchers measure

Primary outcomes

  1. Gut microbiome functional profile.

    Changes in microbial gene functions and metabolic pathways derived from metagenomic analysis.

    Time frame: Baseline and every 2 years over a period of 10 years.

  2. Gut microbiome taxonomic composition

    Changes in faecal microbiome composition assessed by shotgun metagenomic sequencing across menopause stages.

    Time frame: Baseline and 2 years over a period of 10 years.

Secondary outcomes

  1. Female sex hormone levels.

    Blood levels of estradiol, FSH, LH, AMH, and cortisol measured by immunoassays.

    Time frame: Baseline and every 2 years over a period of 10 years.

  2. Inflammation biomarker levels.

    Blood levels of C-reactive protein (CRP), interleukin-6 (IL-6), interleukin-1β (IL-1β) and TNF-α.

    Time frame: Baseline and every two years over a period of 10 years.

  3. Menopause-related symptoms

    Self-reported menopausal symptoms will be assessed via online questionnaires that include reproductive, medical history and associated symptoms.

    Time frame: Baseline and every two years over a period of 10 years.

  4. Nutritional data

    Self-reported dietary intake will be assessed via telephone interview through two 24-hour recalls, following protocols validated by the Portuguese National Food and Physical Activity Survey (IAN-AF).

    Time frame: Baseline and every two years over a period of 10 years.

  5. Effect of physical activity on gut microbiota composition

    Physical activity will be assessed using International Physical Activity Questionnaire - Short Form a validated tool composed of 7 questions covering the last 7 days of physical activity across three intensity levels which allows classification of participants into three activity levels: low, moderate, or high.

    Time frame: Baseline and every two years over a period of 10 years.

  6. Effect of sleeping habits on gut microbiota composition

    Sleeping habits will be assessed by the Pittsburgh Sleep Quality Index (PSQI), a validated questionnaire that consists of 19 items which are distributed into seven "components": subjective sleep quality; sleep latency; sleep duration; habitual sleep efficiency; sleep disturbances; use of sleeping medication; day-time dysfunction. Each component is scored from 0 to 2, and the sum of the component scores yields a global PSQI score. A global PSQI score ≥6 will indicate poor sleep quality.

    Time frame: Baseline and every 2 years over a period of 10 years.

  7. Effect of stress levels on gut microbiota composition

    Stress levels will be assessed by the Perceived Stress Scale, a validated questionnaire composed of 10 questions. Individual scores on the PSS can range from 0 to 40 with higher scores indicating higher perceived stress. Scores ranging from 0-13 will be considered low stress, 14-26 will be considered moderate stress and scores ranging from 27-40 will be considered high perceived stress.

    Time frame: Baseline and every 2 years over a period of 10 years.

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2025 (actual). Primary completion is estimated for Dec 2026, 18 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 11, 2026
First posted
May 29, 2026
StartActual
Jun 2, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2036
Last update
May 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07614542
Lead sponsor
Gulbenkian Institute for Molecular Medicine
Collaborators
Biocodex Microbiota Foundation
Responsible party
Sponsor
First posted
May 29, 2026
Start date
Jun 2, 2025
Primary completion
Dec 2026 (estimated)
Completion
Dec 2036 (estimated)
Last update
May 29, 2026

Study contacts

Ana S Almeida, PhD
Contact
ana.almeida@gimm.pt
+351 217999411
Madalena Reis
Contact
madalena.reis@gimm.pt
+351 217999411

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion